Aura Biosciences, Inc. Logo

Aura Biosciences, Inc.

Developing virus-like therapies to selectively destroy solid tumors in ocular & urologic oncology.

AURA | US

Overview

Corporate Details

ISIN(s):
US05153U1079
LEI:
Country:
United States of America
Address:
80 GUEST STREET, 2135 BOSTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Aura Biosciences, Inc. is a clinical-stage biotechnology company developing a novel class of targeted cancer therapies. The company's proprietary Virus-Like Drug Conjugate (VDC) platform uses Virus-Like Particles (VLPs) to selectively target and destroy solid tumor cells while aiming to preserve healthy tissue. Aura's initial focus is on indications with significant unmet medical needs, particularly in ocular and urologic oncology. Its lead clinical program is being evaluated as a potential first-line treatment for early-stage choroidal melanoma, a rare eye cancer where current treatments often result in vision loss.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Aura Biosciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aura Biosciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aura Biosciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
PAINREFORM LTD. Logo
Specialty pharma developing extended-release drugs for post-operative pain management.
United States of America PRFX
PAION AG Logo
Developed drugs for hospital-based sedation, anesthesia, and critical care.
Germany PA8
PALISADE BIO, INC. Logo
Developing oral precision therapies for inflammatory and fibrotic intestinal diseases like colitis.
United States of America PALI
PALVELLA THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing topical therapies for rare genetic skin diseases.
United States of America PVLA
Pangen Biotech Inc. Logo
Develops biosimilars and provides CHO-based CDMO services for the global biopharma industry.
South Korea 222110
Pasithea Therapeutics Corp. Logo
Developing innovative therapeutics for CNS disorders (ALS, MS) and RASopathies.
United States of America KTTA
Pelthos Therapeutics Inc. Logo
Biopharma with an approved gel for molluscum, advancing a nitric oxide-based pipeline.
United States of America PTHS
Pentixapharm Holding AG Logo
Develops radiopharmaceuticals for diagnosing and treating oncology and adrenal disorders.
Germany PTP
PeopleBio, Inc. Logo
Develops blood tests for early diagnosis of neurodegenerative diseases like Alzheimer's.
South Korea 304840
PEPTONIC Medical AB Logo
Develops clinically proven self-care products for women's intimate health.
Sweden PMED

Talk to a Data Expert

Have a question? We'll get back to you promptly.